BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Industry & Community · 02 Sep 2026
Peptide CDMO Consolidation Accelerates: Samsung Biologics Launches Formal Tender for PolyPeptide as CordenPharma Closes AmbioPharm Deal
Samsung Biologics published its formal tender offer prospectus for Swiss peptide CDMO PolyPeptide Group on 31 August 2026, opening a ten-day cooling-off period ahead of the main acceptance window. The CHF 1.46 billion all-cash bid — carrying a 40 per cent premium to the pre-speculation share price — arrives weeks after CordenPharma completed its acquisition of AmbioPharm, signalling a sharp acceleration in consolidation among specialist peptide contract manufacturers.
Read briefing →
Pharma & GLP-1
CagriSema: The Amylin–GLP-1 Combination With an FDA Decision Due in Q4 2026, a Mixed Trial Record, and No MHRA Pathway Announced
Novo Nordisk's CagriSema — a fixed-dose weekly injection combining semaglutide and the long-acting amylin analogue cagrilintide — is awaiting an FDA decision in the fourth quarter of 2026. The compound produced up to 22.7% weight loss in pivotal trials but failed to demonstrate non-inferiority against tirzepatide in a head-to-head study. No MHRA or EMA regulatory pathway has been announced for the UK or EU.
01 Sep 2026
Reputational Risks
Paradigm Peptides Owner Sentenced to 70 Months: What the First Major Criminal Conviction in the Research-Use-Only Market Means for Research Procurement
A US federal judge sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison on 30 July 2026, after he admitted importing unapproved drugs from China and India and misrepresenting them as domestically manufactured, FDA-registered products. The case is widely regarded as the first significant criminal prosecution in the largely unregulated "research-use only" peptide marketplace, and it carries direct implications for research procurement officers assessing supplier risk.
31 Aug 2026
Research Pipeline
MOTS-c: The Mitochondrial-Encoded Peptide With a Favourable PCAC Vote, Emerging Human Trial Data, and a Long Road to Compounding Approval
MOTS-c received a favourable 7-5 PCAC recommendation on 23 July 2026 for inclusion on the FDA's 503A Bulks List, yet formal rulemaking remains ahead. This briefing examines MOTS-c's mitochondrial mechanism, the state of its preclinical and early clinical evidence, and what the PCAC outcome means for research procurement in the UK and US.
30 Aug 2026
Research Pipeline
Selank: The Tuftsin-Derived Heptapeptide With Russian Regulatory Approval, Modest Western Evidence, and a Changed FDA Compounding Status in 2026
Selank is a synthetic heptapeptide developed in Russia that holds domestic regulatory approval as a prescription anxiolytic and has the most substantial human clinical dataset of any nootropic-class peptide in the Western research conversation. This briefing covers its mechanism, the state of the evidence, its 2026 FDA compounding reclassification, and what that means for UK research-procurement teams.
29 Aug 2026
Research Pipeline
KPV: The Alpha-MSH Tripeptide With an 8-6 PCAC Vote, Two Decades of Preclinical Data, and No Human Clinical Trials
KPV (lysine-proline-valine) is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone with preclinical anti-inflammatory evidence spanning gut, skin, and innate immunity. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend it for the 503A Bulks List — but no human clinical trials have been completed, FDA staff recommended against inclusion, and formal rulemaking has yet to begin.
28 Aug 2026
Pharma & GLP-1
Foundayo (Orforglipron) Lands in UK Pharmacies: What the MHRA Approval and Private Launch Mean for the GLP-1 Landscape
Eli Lilly's oral GLP-1 receptor agonist orforglipron (Foundayo) launched in UK private pharmacies on 24 August 2026, three weeks after the MHRA became the first European regulator to authorise it. As a non-peptide small molecule — not a peptide drug — it represents a structurally distinct route to GLP-1 receptor activation with supply-chain implications that differ from conventional peptide-based agents.
27 Aug 2026
Research Pipeline
TB-500: The Thymosin Beta-4 Fragment With an 8-6 PCAC Vote, Decades of Preclinical Data, and No Human Efficacy Trials
TB-500, the synthetic 17-amino acid fragment of thymosin beta-4, received a favourable 8-6 advisory vote from the FDA's Pharmacy Compounding Advisory Committee on 23 July 2026 — despite agency staff recommending against listing it. No controlled human efficacy trial has yet administered TB-500 directly, making the evidence gap between preclinical promise and regulatory legitimacy unusually pronounced.
26 Aug 2026
Regulatory & Policy
FDA Publishes 17 Revised Draft Product-Specific Guidances for Generic Peptides: What the New Testing Standards Mean
On 28 July 2026, the FDA released revised draft product-specific guidances for 17 injectable peptide products, including semaglutide, tirzepatide, liraglutide, and teriparatide, setting updated standards for bioequivalence, impurity thresholds, and biological activity assessment. The comment window closes 28 September 2026, making this an active regulatory moment for developers and procurement teams alike.
25 Aug 2026
Research Pipeline
Epitalon: The Pineal Tetrapeptide With a PCAC Vote, Four Decades of Russian Research, and No Western Clinical Trials
Epitalon, a synthetic tetrapeptide derived from a pineal-gland extract, received a favourable PCAC recommendation on 24 July 2026 — cleared 7-5 against FDA staff advice. Its evidence base spans four decades of Russian research, compelling in vitro and animal data, and a near-complete absence of independent Western clinical trials. This profile examines the mechanism, the literature, and what the regulatory development means for UK research procurement.
24 Aug 2026
Research Pipeline
CJC-1295 and Ipamorelin: Mechanism, Evidence Base, and Regulatory Position in 2026
CJC-1295 and ipamorelin are the two most widely researched growth hormone secretagogue peptides in research procurement. Both remain on the FDA's Category 2 list pending further review, carry a mechanistically coherent combined-use rationale, and yet lack the clinical trial depth that would support approved compounding. This briefing covers their pharmacology, the state of the evidence, and what their regulatory position means for UK research laboratories.
23 Aug 2026
Pharma & GLP-1
Samsung Biologics' $1.8 Billion Bid for PolyPeptide: What the Largest Peptide CDMO Acquisition of 2026 Means for the Supply Chain
Samsung Biologics has launched a CHF 1.46 billion all-cash tender offer to acquire Swiss peptide CDMO PolyPeptide Group, with the formal prospectus due by end of August 2026. The deal — the largest peptide manufacturing acquisition of the year — reflects structural demand for GLP-1 API capacity and signals a further consolidation of the CDMO landscape that research-procurement teams should factor into sourcing strategy.
22 Aug 2026